Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$170.96
▲ $0.61 (+0.4%)
Market data updated: 09/20 06:07 PM
News analyzed: 09/20/2026
Market Cap
$6.73B
Day Range
$169.31 - $172.22
52-Week Range
$68.21 - $200.00
Beta
—
Next Earnings
09.11.2026
Support
$144.06
Resistance
$198.58
BLTE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+133.4% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 7/14 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Golden Cross
SMA 50 recently crossed above SMA 200
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 4.4% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Belite Bio (BLTE) demonstrates a robust overall investor score of 78, driven primarily by strong technical performance and positive news sentiment, though tempered by notable risk factors. The technical category scores 81, reflecting a clear upward momentum with the stock price consistently trading above both the 50-day and 200-day moving averages, alongside a positive MACD histogram indicating rising momentum. However, the RSI (74.0) and %K (99.4) metrics signal overbought conditions, suggesting potential short-term volatility or a pullback. The news category scores even higher at 86, buoyed by recent positive analyst coverage—including a 'Buy' rating from Canaccord—and regulatory progress in Japan for its Stargardt disease drug candidate, though mixed revenue estimates and regulatory hurdles introduce nuanced concerns. The risk category, scoring 50, highlights volatility with a 36.6% maximum drawdown over three years and a relatively high ATR (4.1%), indicating potential price swings. These factors collectively suggest a stock with strong growth potential but requiring cautious monitoring of overvaluation risks and volatility.
The stock price is above both the 50-day and 200-day moving averages, with a positive MACD histogram indicating upward momentum, though RSI (74.0) and %K (99.4) suggest overbought conditions.
This indicates strong short-to-medium-term momentum but also signals potential overvaluation or imminent pullback risk.
Recent analyst upgrades (e.g., Canaccord 'Buy' rating) and regulatory progress in Japan for Tinlarebant offset mixed revenue estimates and neutral/negative news items.
Positive analyst sentiment and regulatory milestones can drive investor confidence, while revenue uncertainties may introduce caution.
The ATR (4.1%) and a 36.6% maximum drawdown over three years highlight significant volatility and downside risk.
High volatility and past drawdowns suggest the stock may experience sharp price swings, requiring risk management.
StockIQ conclusion
Belite Bio (BLTE) presents a balanced profile with strong technical momentum and positive news sentiment, supported by regulatory progress and analyst optimism. However, elevated volatility, overbought conditions, and mixed revenue expectations introduce caution. The stock’s performance hinges on continued clinical and regulatory success, particularly in Japan, while investors should monitor volatility and potential pullbacks. The overall outlook remains cautiously optimistic but requires vigilant risk management.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
70
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $171.00
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
1d ago · $171.00
Evidence: 6 bullish / 3 bearish technical signals agreeing
What happened after
Still awaiting outcome
6d ago · $175.47
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
6d ago · $175.47
Evidence: 1.8x recent average volume
What happened after
Still awaiting outcome
6d ago · $175.47
Evidence: 8 bullish / 0 bearish technical signals agreeing
What happened after
Still awaiting outcome
6d ago · $173.79
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
6d ago · $173.79
Evidence: 1.8x recent average volume
What happened after
Still awaiting outcome
6d ago · $173.79
Evidence: 8 bullish / 0 bearish technical signals agreeing
What happened after
Still awaiting outcome
7d ago · $173.79
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
7d ago · $173.79
Evidence: 1.8x recent average volume
What happened after
Still awaiting outcome
7d ago · $173.79
Evidence: 8 bullish / 0 bearish technical signals agreeing
What happened after
Still awaiting outcome
9d ago · $175.07
Evidence: -3.1pp vs. sector average today
What happened after
Still awaiting outcome
9d ago · $175.07
Evidence: -6.8pp vs. sector average today
What happened after
Still awaiting outcome
9d ago · $175.07
Evidence: -3.1pp vs. sector average today
What happened after
Still awaiting outcome
10d ago · $179.58
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
10d ago · $179.58
Evidence: 1.6x recent average volume
What happened after
10d ago · $179.58
Evidence: 10 bullish / 0 bearish technical signals agreeing
What happened after
11d ago · $185.04
Evidence: -3.3pp vs. sector average today
What happened after
11d ago · $185.04
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
11d ago · $185.04
Evidence: 1.6x recent average volume
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 10, 2026
Then
86
$183.16
Now
70
$170.96
What happened since
Signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
70
Risk
50
Sentiment
80
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Belite Bio Inc.** has centered on its **tinlarebant**, an investigational oral therapy for **Stargardt Disease Type 1 (STGD1)**, with key focus on its **Japan regulatory progress**—notably submitting a **New Drug Application (NDA) under Japan’s Sakigake program** for accelerated review. Analysts, including **HC Wainwright and Canaccord**, have raised **price targets** ($245, $303) and issued **Buy ratings**, citing potential revenue growth and FDA priority review momentum. The company’s stock has seen **upward movement** tied to these positive analyst actions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Belite Bio Inc. News trend score: 80. Reason: 10 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
22
🎯 Conviction (vs. Emotion)
50
Psychology
25
Fundamentals
—
Technical
70
Valuation
—
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+17%
Market Narrative
67
Fundamental Reality
50
Narrative Gap
+17
🧠 StockIQ Psychologist
BLTE’s market behavior suggests a dominant FOMO-driven rally, reinforced by extreme technical readings and near-unanimous positive sentiment. The narrative gap (83 vs. 50) implies investors may be overestimating tailwinds, while anchoring near resistance hints at potential profit-taking. The key question is whether momentum can sustain itself or if euphoria will trigger a pullback. Herding remains muted, suggesting no broad sector-wide contagion, but the overbought RSI and extreme Bollinger %B signal caution ahead.
Updated: 09/09/2026, 11:38 AM
What could change this?
👥 What the crowd believes
"Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant."
"Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant."
"Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says"
🧠 Market Brain events driving this
📈 16D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 61/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark contrast between Jesse Livermore’s high score (77) and the overwhelming caution from the rest of the methodologies highlights a fundamental divide in how these investors approach this stock. Livermore’s positive verdict stems from a clear price-action trend that aligns with his technical, momentum-driven philosophy, while the majority—particularly Howard Marks, Gerald Loeb, and Samuel Armstrong Nelson—flag red flags like valuation risk, late-cycle positioning, and overbought conditions. Meanwhile, the lack of definitive verdicts from Graham, Fisher, Lynch, and Bagehot suggests insufficient fundamental or balance-sheet data to apply their rigorous frameworks, leaving their models neutral. Even the efficient-market approach leans mixed, implying no clear edge over passive indexing, further isolating Livermore’s bullish stance.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 61
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 55
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 50
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 46
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 32
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 26
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (6 bullish · 3 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 10 positive, 5 neutral, 5 negative out of the last 20 articles.
SeekingAlpha · 14.9.2026
MT Newswires · 10.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
MT Newswires · 9.9.2026
Benzinga · 9.9.2026
SeekingAlpha · 9.9.2026
Benzinga · 8.9.2026
MT Newswires · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 8.9.2026
MT Newswires · 4.9.2026
MT Newswires · 4.9.2026
Yahoo · 4.9.2026
The Fly · 4.9.2026
Benzinga · 4.9.2026
Yahoo · 4.9.2026
24/7 Wall St. · 4.9.2026
MT Newswires · 4.9.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Belite Bio Inc (BLTE) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for BLTE specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
BLTE's technical score is 70/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: SMA 50 recently crossed above SMA 200; Calmar: 2.09 (3y annualized return 76.5% / max drawdown 36.6%); Price is above the 50-day average.
Based on the real signals StockIQ computed: ATR: 4.4% of price; MACD histogram is negative — falling momentum; Price is below the SAR point — downtrend.
StockIQ has no recorded dividend payment history for BLTE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 25 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Chuang Hao-Yuan | Open Market Sale | 8.9.2026 | 2,200 | -2,200 | $194.28 |
| Chuang Hao-Yuan | Open Market Sale | 8.9.2026 | 4,120 | -4,120 | $195.60 |
| Chuang Hao-Yuan | Open Market Sale | 8.9.2026 | 2,562 | -2,562 | $198.05 |
| Chuang Hao-Yuan | Open Market Sale | 8.9.2026 | 4,475 | -4,475 | $196.47 |
| Chuang Hao-Yuan | Open Market Sale | 8.9.2026 | 4,605 | -4,605 | $197.23 |
| Lin Yu-Hsin | Open Market Sale | 8.9.2026 | 2,400 | -2,400 | $194.33 |
| Lin Yu-Hsin | Open Market Sale | 8.9.2026 | 2,700 | -2,700 | $198.09 |
| Lin Yu-Hsin | Open Market Sale | 8.9.2026 | 6,058 | -6,058 | $196.54 |
| Lin Yu-Hsin | Open Market Sale | 8.9.2026 | 8,752 | -8,752 | $197.36 |
| Lin Yu-Hsin | Open Market Sale | 8.9.2026 | 6,090 | -6,090 | $195.62 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 3,398 | -3,398 | $192.40 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 4,602 | -4,602 | $193.12 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 6,200 | -6,200 | $191.09 |
| Lin Yu-Hsin | Open Market Sale | 4.9.2026 | 600 | -600 | $190.39 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 1,800 | -1,800 | $190.63 |
| Lin Yu-Hsin | Open Market Sale | 4.9.2026 | 6,200 | -6,200 | $187.25 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 1,900 | -1,900 | $188.59 |
| Lin Yu-Hsin | Open Market Sale | 4.9.2026 | 4,209 | -4,209 | $192.54 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 1,633 | -1,633 | $180.16 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 2,000 | -2,000 | $182.49 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 3,900 | -3,900 | $187.16 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 2,000 | -2,000 | $181.05 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 3,872 | -3,872 | $185.28 |
| Lin Yu-Hsin | Open Market Sale | 4.9.2026 | 3,045 | -3,045 | $188.26 |
| Chuang Hao-Yuan | Open Market Sale | 4.9.2026 | 4,600 | -4,600 | $186.35 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,049,817 shares short as of 2026-08-31 · vs. 1,134,633 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.0% of trading volume this week was short selling, vs. 62.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology